Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adenosine A1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | adenosine A2a receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | follicle stimulating hormone receptor | adenosine A2a receptor | 412 aa | 336 aa | 22.3 % |
Brugia malayi | hypothetical protein | adenosine A1 receptor | 326 aa | 305 aa | 21.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.1765 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.1765 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.1765 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.1765 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1765 | 0.5 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1765 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.1765 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.1765 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.1765 | 0.5 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.1765 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.1765 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.1765 | 0.5 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.1765 | 0.5 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.1765 | 0.5 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.1765 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1765 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1765 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.1765 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1765 | 0.5 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.1765 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | Reversal of haloperidol-induced catalepsy in po dosed balb/c mouse compound administered 30 mins post challenge | ChEMBL. | No reference | |
Ki (binding) | = 130 nM | Antagonist activity at human adenosine A1 receptor expressed in CHO-K1 cells preincubated for 15 mins before r-PIA addition measured after 5.5 to 6 hrs by beta-galactosidase reporter gene assay | ChEMBL. | No reference |
Ki (functional) | > 10000 nM | Antagonist activity at human adenosine A2A receptor expressed in CHO-K1 cells preincubated for 15 mins before NECA addition measured after 5.5 to 6 hrs by beta-galactosidase reporter gene assay | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.